Dr Reddy's completes two acquisitions

Dr Reddy's Laboratories has completed two acquisitions. The Indian generics giant has bought USA-based Dow Chemical Company's Dowpharma  Small Molecules Business associated with its Mirfield and Cambridge, UK,  sites and German chemicals firm BASF's drug contract manufacturing  business and related facility in Shreveport, Louisiana, USA. Financial  terms and conditions of the transactions were not disclosed.

The acquisition of the Dowpharma Small Molecules Business associated  with the two UK sites includes the relevant business, customer  contracts, associated products, process technology, intellectual  property and trade marks as well as the transfer of the Mirfield and  Cambridge facilities. Employees directly related to the business  located at the Cambridge and Mirfield sites will remain employed by Dr  Reddy's. The Indian firm will also have a non-exclusive license to Dow's  Pf-nex Expression Technology for biocatalysis development.

The acquisition of BASF's US contract manufacturing business and related  facility includes the relevant business, customer contracts, related  Abbreviated New Drug Applications and New Drug Applications, trade  marks, as well as the manufacturing facility and assets at Shreveport.  It also includes a tolling and supply agreement. Employees directly  related to the business located at Shreveport site will become part of  Dr Reddy's staff.